Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/intubation 67% Improvement Relative Risk Aspirin for COVID-19  Tse et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? PSM retrospective 2,664 patients in China (January - December 2020) Lower death/intubation with aspirin (p=0.00027) c19early.org Tse et al., Heart, June 2023 Favors aspirin Favors control

Aspirin is associated with lower risks of severe covid-19 disease: a population-based study

Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
24th treatment shown to reduce risk in August 2021
 
*, now known with p = 0.000087 from 73 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
PSM retrospective 2,664 COVID-19 hospitalized patients receiving steroids/antiviral therapy in Hong Kong, showing lower risk of combined death/intubation with aspirin use.
risk of death/intubation, 67.0% lower, OR 0.33, p < 0.001, adjusted per study, propensity score matching, multivariable, day 30, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tse et al., 2 Jun 2023, retrospective, China, peer-reviewed, 12 authors, study period 1 January, 2020 - 8 December, 2020.
This PaperAspirinAll
Abstract: Abstracts 210 Emmanouela Kampouraki. 10.1136/heartjnl-2023-BCS.210 Introduction It is estimated that statin non-adherence reaches 50% in patients with hyperlipidaemia. Factors related to the healthcare system, among others, play an important role in statin non-adherence. We designed and tested a modified version of the MYMEDS© tool (1), called The My Experience of Taking Statin Medicines (mySTATINmed) online questionnaire, which examined the presence of modifiable barriers to adherence to support patients on statins. The impact of consultation experience with healthcare professionals on the display of potential or actual barriers to adherence was extracted from the questionnaire. Methods The mySTATINmed questionnaire explored patient perspectives on the main modifiable factors that are likely to be associated with statin non-adherence, including the consultation experience with healthcare professionals and the level of information received during consultations. Information included the mechanism of action of statins, their expected benefit, treatment duration, expected side effects, management of side effects and lifestyle changes needed. The quality of consultation experience and the level of information received during consultation were analysed in relation to the display of potential or actual barriers to adherence. Chi-squared test was used to compare the frequencies. Results The mySTATINmed questionnaire was responded by 466 patients [59% males; age mean±SD (range): 65±11 (2186) years] across 29 GP Practices in Leeds. Based on responses in four questionnaire domains (shown in Table 1), the level of display of potential or actual barriers to adherence was scored. Based on this score, patients were then dichotomised between adherent (54%) and non-adherent (46%). Overall, the mySTATINmed detected that 46% of participants displayed some level of actual or potential barriers to statin adherence based on their responses. A greater proportion of patients in the adherent versus the non-adherent group rated their consultation experience highly (72% v 57% respectively; p<0.001) and reported having received enough Abstract 210 Table 1 Core mySTATINmed domains which were included in the display of potential or actual barriers to adherence score. Comparison of adherent/non-adherent scores per domain Questionnaire domain and Non-adherent Adherent p-value (chi-sq score (%) (%) test) <0.001 information during consultations (56% v 43% respectively; p=0.003). The type and level of information shared during consultations and the quality of consultation positively correlated with adherence (Table 1). Conclusions The mySTATINmed is a simple tool which identified the level of display of potential or actual barriers to statin adherence, which in turn can inform a better structured, personalised statin consultation. A good consultation experience is associated with better statin adherence. Conflict of Interest None 211 ASPIRIN IS ASSOCIATED WITH LOWER RISKS OF SEVERE COVID-19 DISEASE: A POPULATION-BASED STUDY 1 Gary Tse, 2Qingpeng Zhang, 3Abraham Wai, 4Emma King, 5Keith Leung, 6Sharen Lee, Carlin Chang, 3Ian Wong, 3Bernard Cheung, 8Jiandong Zhou, 9Tong Liu, 3Hok Him Pui. 1 Hong Kong Metropolitan University; 2City University of Hong Kong; 3The University of Hong Kong; 4Cardiovascular Analytics Group; 5Aston University / The University of Hong Kong; 6Chinese University of Hong Kong; 7Queen Mary Hospital; 8University of Oxford; 9 Second..
{ 'DOI': '10.1136/heartjnl-2023-bcs.211', 'URL': 'http://dx.doi.org/10.1136/heartjnl-2023-BCS.211', 'alternative-id': ['10.1136/heartjnl-2023-BCS.211'], 'author': [ {'affiliation': [], 'family': 'Tse', 'given': 'Gary', 'sequence': 'first'}, {'affiliation': [], 'family': 'Zhang', 'given': 'Qingpeng', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Wai', 'given': 'Abraham', 'sequence': 'additional'}, {'affiliation': [], 'family': 'King', 'given': 'Emma', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Leung', 'given': 'Keith', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lee', 'given': 'Sharen', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chang', 'given': 'Carlin', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Wong', 'given': 'Ian', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Cheung', 'given': 'Bernard', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Zhou', 'given': 'Jiandong', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Liu', 'given': 'Tong', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Pui', 'given': 'Hok Him', 'sequence': 'additional'}], 'container-title': 'Stable IHD/Prevention/Hypertension/Lipids', 'content-domain': {'crossmark-restriction': True, 'domain': ['bmj.com']}, 'created': {'date-parts': [[2023, 7, 17]], 'date-time': '2023-07-17T17:00:31Z', 'timestamp': 1689613231000}, 'deposited': { 'date-parts': [[2023, 7, 17]], 'date-time': '2023-07-17T17:00:33Z', 'timestamp': 1689613233000}, 'event': 'British Cardiovascular Society Annual Conference, ‘Future-proofing Cardiology for the next 10 ' 'years’, 5–7 June 2023', 'indexed': {'date-parts': [[2023, 7, 18]], 'date-time': '2023-07-18T04:24:23Z', 'timestamp': 1689654263580}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2023, 6]]}, 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/heartjnl-2023-BCS.211', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '239', 'original-title': [], 'prefix': '10.1136', 'published': {'date-parts': [[2023, 6]]}, 'published-online': {'date-parts': [[2023, 6, 2]]}, 'published-print': {'date-parts': [[2023, 6]]}, 'publisher': 'BMJ Publishing Group Ltd and British Cardiovascular Society', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://heart.bmj.com/lookup/doi/10.1136/heartjnl-2023-BCS.211'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'title': '211\u2005Aspirin is associated with lower risks of severe covid-19 disease: a population-based ' 'study', 'type': 'proceedings-article', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit